COMPOUND OVERVIEW

Semax is a synthetic heptapeptide derived from the ACTH(4-7) fragment, extended with a Pro-Gly-Pro sequence. Originally developed in Russia, it was created as a nootropic and neuroprotective research compound targeting the central nervous system. Semax is notable for its ability to modulate brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and serotonin systems, making it a compelling research tool in neurological and cognitive function studies. Unlike its precursor ACTH, Semax lacks hormonal activity — it does not stimulate cortisol release — focusing its effects exclusively on CNS and neuroprotective pathways.

MECHANISM OF ACTION

Semax’s primary mechanism involves upregulation of BDNF and NGF expression in the hippocampus and cortex, with resulting downstream activation of TrkB receptors. It modulates serotonergic and dopaminergic tone, and has demonstrated membrane-stabilizing and antioxidant properties in neuronal cell cultures. Semax also inhibits enkephalin-degrading enzymes, increasing endogenous opioid availability in the CNS. Research suggests it crosses the blood-brain barrier when administered intranasally, activating neuroplasticity pathways with minimal systemic endocrine effects due to the absence of the ACTH steroidogenic domain.

RESEARCH APPLICATIONS

• Neuroprotection and brain injury research models
• BDNF and NGF upregulation studies
• Cognitive function, memory, and neuroplasticity research
• Stroke and ischemia recovery research models
• Anxiety and stress response modulation research
• Serotonergic and dopaminergic pathway studies
• Intranasal peptide delivery and CNS bioavailability research

KEY RESEARCH FINDINGS

• Research demonstrates Semax significantly upregulates BDNF mRNA expression in rat hippocampus following administration
• Ischemia studies in rat models show reduced infarct volume and improved neurological outcomes with Semax treatment
• Cognitive research indicates improved memory formation and retention in animal models with acute and chronic Semax administration
• Studies confirm intranasal Semax crosses the BBB and reaches relevant CNS concentrations within minutes
• Anti-anxiety effects confirmed in multiple preclinical models through serotonergic modulation
• NGF upregulation research supports potential applications in neurodegenerative disease models

STORAGE & HANDLING

• Store lyophilized powder at -20°C; stable up to 24 months
• Reconstitute with sterile saline or bacteriostatic water; store at 2–8°C
• Intranasal delivery requires appropriate research-grade nasal delivery devices
• Use within 14 days of reconstitution for optimal stability
• Protect from light and keep in sealed, sterile conditions

SPECIFICATIONS

DISCLAIMER: This compound is sold strictly for laboratory and research purposes only. It is not intended for human consumption, clinical use, or veterinary application. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. For use by licensed researchers and qualified professionals only. You must be 21 years of age or older to purchase.

usaminopeptides.com · For Researcher Inquiries Contact: info@usaminopeptides.com